Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for BioNTech SE (BNTX) through the VizualStocks API.
Revenue recognized by BioNTech from worldwide Comirnaty COVID-19 vaccine supply and sales during the period, including direct customer sales, supplies to collaboration partners, and its share of partners’ gross profit and applicable sales milestones. Partner profit shares are net amounts, rather than total end-market vaccine sales.
covid19VaccineRevenueBioNTech revenue outside COVID-19 vaccines and separately reported out-licensing, including pandemic preparedness services and R&D collaborations. Values for 2021-2022 combine other sales and R&D collaboration revenue.
otherRevenueRevenue BioNTech recognizes from out-licensing intellectual property, including the pumitamig (BNT327/BMS986545) collaboration with Bristol Myers Squibb. This is recognized revenue for the period, rather than cash receipts, deferred revenue, or potential future milestone payments.
outLicensingRevenueBioNTech revenue recognized when goods or services transfer at a point in time, across all revenue types.
revenueRecognizedAtPointInTimeBioNTech revenue recognized as goods or services transfer over time, across all revenue types.
revenueRecognizedOverTimeBioNTech revenue recognized under the sales- or usage-based royalty model, including its share of collaboration partners’ gross profit and applicable sales milestones.
salesBasedRoyaltyRevenue